loading
Phibro Animal Health Corp. stock is currently priced at $12.73, with a 24-hour trading volume of 75,361. It has seen a +2.33% increased in the last 24 hours and a -0.86% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $12.45 pivot point. If it approaches the $12.78 resistance level, significant changes may occur.
Previous Close:
$12.44
Open:
$12.41
24h Volume:
75,361
Market Cap:
$515.61M
Revenue:
$982.01M
Net Income/Loss:
$14.80M
P/E Ratio:
15.52
EPS:
0.82
Net Cash Flow:
$37.02M
1W Performance:
-4.29%
1M Performance:
-0.86%
6M Performance:
+17.11%
1Y Performance:
-17.07%
1D Range:
Value
$12.41
$12.83
52W Range:
Value
$9.40
$15.96

Phibro Animal Health Corp. Stock (PAHC) Company Profile

Name
Name
Phibro Animal Health Corp.
Name
Phone
201-329-7300
Name
Address
Glenpointe Centre East, 3rd Floor Suite 21 300 Frank West Burr Boulevard, Teaneck, NJ
Name
Employee
1,500
Name
Twitter
@phibroeurope
Name
Next Earnings Date
2024-05-09
Name
Latest SEC Filings
Name
PAHC's Discussions on Twitter

Phibro Animal Health Corp. Stock (PAHC) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-21-22 Initiated ROTH Capital Buy
Jul-25-22 Downgrade Barclays Equal Weight → Underweight
Jan-10-22 Upgrade Barclays Underweight → Equal Weight
Nov-18-21 Initiated Morgan Stanley Equal-Weight
Aug-05-21 Resumed Credit Suisse Neutral
Jul-07-21 Downgrade Barclays Equal Weight → Underweight
Aug-06-20 Downgrade Morgan Stanley Equal-Weight → Underweight
Feb-06-20 Downgrade Gabelli & Co Buy → Hold
Jan-28-20 Upgrade Barclays Underweight → Equal Weight
Sep-05-19 Upgrade Morgan Stanley Underweight → Equal-Weight
Aug-29-19 Reiterated BofA/Merrill Underperform
Jun-11-19 Initiated Barclays Underweight
May-23-19 Initiated Guggenheim Neutral
May-09-19 Upgrade Gabelli & Co Hold → Buy
Aug-23-17 Resumed BofA/Merrill Underperform
Jun-02-17 Downgrade Credit Suisse Outperform → Neutral
Dec-15-16 Initiated Piper Jaffray Overweight
Nov-11-16 Downgrade Macquarie Neutral → Underperform
Nov-10-16 Downgrade Gabelli & Co Buy → Hold
Apr-11-16 Reiterated Guggenheim Buy
Feb-04-16 Initiated Credit Suisse Outperform
Jan-15-16 Downgrade Barclays Overweight → Underweight
Sep-30-15 Initiated Gabelli & Co Buy
Apr-24-15 Reiterated Barclays Overweight
Apr-21-15 Downgrade Morgan Stanley Equal-Weight → Underweight
May-06-14 Initiated Barclays Overweight
View All

Phibro Animal Health Corp. Stock (PAHC) Financials Data

Phibro Animal Health Corp. (PAHC) Revenue 2024

PAHC reported a revenue (TTM) of $982.01 million for the quarter ending December 31, 2023, a +1.02% rise year-over-year.
loading

Phibro Animal Health Corp. (PAHC) Net Income 2024

PAHC net income (TTM) was $14.80 million for the quarter ending December 31, 2023, a -59.17% decrease year-over-year.
loading

Phibro Animal Health Corp. (PAHC) Cash Flow 2024

PAHC recorded a free cash flow (TTM) of $37.02 million for the quarter ending December 31, 2023, a +161.31% increase year-over-year.
loading

Phibro Animal Health Corp. (PAHC) Earnings per Share 2024

PAHC earnings per share (TTM) was $0.37 for the quarter ending December 31, 2023, a -58.89% decline year-over-year.
loading
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Israel, Latin America, Canada, Europe, Africa, and the Asia/Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. The company is headquartered in Teaneck, New Jersey. Phibro Animal Health Corporation is a subsidiary of BFI Co., LLC.
$13.26
price up icon 1.69%
$73.26
price up icon 1.57%
$55.92
price up icon 0.22%
drug_manufacturers_specialty_generic RDY
$74.55
price up icon 0.72%
$135.99
price down icon 1.28%
$11.57
price up icon 0.87%
Cap:     |  Volume (24h):